Skip to main content

Atea Pharmaceuticals, Inc.

AVIR
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001593899

No open-market purchases or sales by Atea Pharmaceuticals, Inc. insiders were filed in the last 90 days; 124 institutions reported holding it in 13F filings for Q2 2026, worth $276.4M in total; no superinvestor holds it.

Q2 2024 vs. Q1 2024

How the institutions holding Atea Pharmaceuticals, Inc. changed between Q1 2024 and Q2 2024.

All holders in Q2 2024All holders in Q1 2024

13F holders of AVIR: Q1 2024 compared with Q2 2024
MeasureQ1 2024Q2 2024Change
Holders113105−8
Shares54.4M56.7M+2.33M (+4.3%)
Value$219.6M$187.7M−$32.0M (−14.6%)

New holders (13)

Institutions that held Atea Pharmaceuticals, Inc. at the end of Q2 2024 but not at the end of Q1 2024.

Institutions new to AVIR in Q2 2024
InstitutionSharesValue% of portfolio
Almitas Capital LLC1,290,187$4.27M1.78%
Marshall Wace, LLP182,326$603.5K0.00%
Verition Fund Management LLC65,976$218.4K0.00%
Berkshire Asset Management LLC65,000$215.2K0.01%
Corebridge Financial, Inc.41,513$137.4K0.00%
Mirae Asset Global ETFs Holdings Ltd.39,048$129.2K0.00%
State Board of Administration of Florida Retirement System22,010$72.9K0.00%
Redwood Wealth Management Group, LLC5,000$16.6K0.01%
Jones Financial Companies LLLP207$6850.00%
EverSource Wealth Advisors, LLC118$4510.00%
Smartleaf Asset Management LLC46$1550.00%
CWM, LLC20$00.00%
Covestor Ltd118$00.00%

Sold out (21)

Institutions that held Atea Pharmaceuticals, Inc. at the end of Q1 2024 and filed for Q2 2024 without it.